Aspirin use and early age-related macular degeneration: A meta-analysis

Canadian Journal of Ophthalmology

Volumn 49, Issue 1, 2014, Pages 35-39

  Kahawita, Shyalle K ^a   Casson, Robert J ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; DRUG USE; HUMAN; META ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; RISK; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DATABASES, FACTUAL; HUMANS; MACULAR DEGENERATION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS;

EID: 84901333504     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2013.07.016     Document Type: Article

References (34)

1. American Academy of Ophthalmology Retina Panel. Age-related macular degeneration. San Francisco, Calif: American Academy of Ophthalmology; 2008. Retrieved from www.aao.org/ppp. Accessed February 4, 2013.
2. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012; 379: 1728-38.
3. Holliday EG, Smith AV, Cornes BK, et al. Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis. PLoS One. 2013; 8: e53830.
4. Miller JW. Age-related macular degeneration revisited - piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Oph-thalmol. 2013; 155: 1-35.e13.
5. He S, Li X, Chan N, Hinton DR. Review: epigenetic mechanisms in ocular disease. Mol Vis. 2013; 19: 665-74.
6. Viringipurampeer IA, Bashar AE, Gregory-Evans CY, Moritz OL, Gregory-Evans K. Targeting inflammation in emerging therapies for genetic retinal disease. Int J Inflamm. 2013; 2013: 581751.
7. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epide-miological Study Group. Surv Ophthalmol. 1995; 39: 367-74.
8. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010; 128: 750-8.
9. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995; 102: 1450-60.
10. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000; 107: 1593-600.
11. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007; 114: 253-62.
12. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001; 119: 1417-36.
13. Klein BE, Howard KP, Gangnon RE, Dreyer JO, Lee KE, Klein R. Long-term use of aspirin and age-related macular degeneration. JAMA. 2012; 308: 2469-78.
14. Christen WG, Manson JE, Glynn RJ, et al. Low-dose aspirin and risk of cataract and subtypes in a randomized trial of U.S. physicians. Ophthalmic Epidemiol. 1998; 5: 133-42.
15. Hennekens CH, Dalen JE. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. Am J Med. 2013; 126: 373-8.
16. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. New Engl J Med. 1989; 321: 129-35.
17. Liew G, Mitchell P, Wong TY, Rochtchina E, Wang JJ. The association of aspirin use with age-related macular degeneration. JAMA Int Med. 2013; 173: 258-64.
18. de Jong PT, Chakravarthy U, Rahu M, et al. Associations between aspirin use and aging macula disorder: the European Eye Study. Ophthalmology. 2012; 119: 112-8.
19. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related mac-ular degeneration. Am J Ophthalmol. 2004; 137: 615-24.
20. Zhu W, Wu Y, Xu D, et al. Aspirin use and risk of age-related macular degeneration: a meta-analysis. PLoS One. 2013; 8:e58821.
21. Christen WG, Glynn RJ, Ajani UA, et al. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol. 2001; 119: 1143-9.
22. Christen WG, Glynn RJ, Chew EY, Buring JE. Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology. 2009; 116: 2386-92.
23. Douglas IJ, Cook C, Chakravarthy U, Hubbard R, Fletcher AE, Smeeth L. A case-control study of drug risk factors for age-related macular degeneration. Ophthalmology. 2007; 114: 1164-9.
24. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000; 107: 2224-32.
25. Moon BG, Joe SG, Hwang JU, Kim HK, Choe J, Yoon YH. Prevalence and risk factors of early-stage age-related macular degeneration in patients examined at a health promotion center in Korea. J Korean Med Sci. 2012; 27: 537-41.
26. Klein R, Klein BE, Jensen SC, et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2001; 119: 1354-9.
27. Cheung N, Tay WT, Cheung GC, Wang JJ, Mitchell P, Wong TY. Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study. Br J Ophthalmol. 2013; 97: 785-8.
28. de Jong PT. Aspirin and age-related macular degeneration. Ophthalmology. 2010; 117: 1279-80; (author reply 80).
29. Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120: 844-51.
30. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010; 10: 31.
31. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 1999; 6: 125-43.
32. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol. 1998; 116: 583-7.
33. Klein R, Cruickshanks KJ, Myers CE, et al. The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: the Beaver Dam studies. Ophthalmology. 2013; 120: 1012-9.
34. Hirvela H, Luukinen H, Laara E, Sc L, Laatikainen L. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology. 1996;103(6): 871-7.